SBT-272 Phase 1 safety and tolerability data support further clinical development
SBT-272 was neuroprotective and reduced neuroinflammation in ALS preclinical model
SBT-272 Granted Orphan Drug Designation for Treatment of ALS
https://www.biospace.com/article/releases/stealth-biotherapeutics-announces-sbt-272-data-updates-and-orphan-drug-designation-for-the-treatment-of-amyotrophic-lateral-sclerosis-als-/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.